In cancer, plasma-derived cell-free DNA can be used for detection of oncogenic aberrations relevant for treatment selection. A cell-free DNA-based test for EGFR mutations has been approved as an alternative to tumor tissue analysis in lung cancer. Testing for other aberrations, including copy number alterations, continues to be investigated. Clin Cancer Res; 22(22); 5400–2. ©2016 AACR.
See related article by Chicard et al., p. 5564
- Received July 29, 2016.
- Accepted September 6, 2016.
- ©2016 American Association for Cancer Research.